Literature DB >> 3928732

The effects of growth hormone-releasing factor (GRF) and dopamine on growth hormone (GH) secretion in acromegaly.

M Giusti, A Lomeo, G Mazzocchi, D Mignone, P Sessarego, M Monachesi, G Giordano.   

Abstract

GRF (1-40), dopamine (DA), DA plus GRF and placebo were administered to 6 acromegalic patients. The GRF administration induced a highly variable GH release (GH delta % 167.3 +/- 21.4; mean +/- SE). GRF did not provoke any change in PRL serum levels. During simultaneous GRF and DA administration GH release was found to be reduced (GH delta % 80.2 +/- 17.8) compared to that observed for a corresponding period of time after GRF alone (p less than 0.05). Our data underscore that in acromegaly the DA tonus inhibits GH secretion after GRF by acting directly at the pituitary level.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3928732     DOI： 10.1007/BF03348478

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


  16 in total

1.  Sleep-wake behavior and integrated values of LH, FSH, PRL, FH and TSH in Klinefelter's syndrome.

Authors:  M Giusti; R Mortara; F Bolognesi; D Mignone; G Giordano
Journal:  J Endocrinol Invest       Date:  1979 Oct-Dec       Impact factor: 4.256

2.  Somatostatin sensitivity and growth hormone responses to releasing hormones and bromocryptine in acromegaly.

Authors:  G F Pieters; J E Romeijn; A G Smals; P W Kloppenborg
Journal:  J Clin Endocrinol Metab       Date:  1982-05       Impact factor: 5.958

3.  Comparative study of human fetal, normal adult, and somatotropic adenoma pituitary function in tissue culture.

Authors:  S Marcovitz; C G Goodyer; H Guyda; R J Gardiner; J Hardy
Journal:  J Clin Endocrinol Metab       Date:  1982-01       Impact factor: 5.958

4.  Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour.

Authors:  J Rivier; J Spiess; M Thorner; W Vale
Journal:  Nature       Date:  1982-11-18       Impact factor: 49.962

5.  A case for hypothalamic acromegaly: a clinicopathological study of six patients with hypothalamic gangliocytomas producing growth hormone-releasing factor.

Authors:  S L Asa; B W Scheithauer; J M Bilbao; E Horvath; N Ryan; K Kovacs; R V Randall; E R Laws; W Singer; J A Linfoot
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

6.  Human pancreatic growth-hormone-releasing factor selectively stimulates growth-hormone secretion in man.

Authors:  M O Thorner; J Rivier; J Spiess; J L Borges; M L Vance; S R Bloom; A D Rogol; M J Cronin; D L Kaiser; W S Evans; J D Webster; R M MacLeod; W Vale
Journal:  Lancet       Date:  1983-01-01       Impact factor: 79.321

7.  Growth hormone releasing factor (hpGRF)-stimulation test in normal controls and acromegalic patients.

Authors:  K von Werder; O A Müller; R Hartl; M Losa; G K Stalla
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

8.  [Acromegaly, clinical expression of the production of growth hormone releasing factor in pancreatic tumors].

Authors:  G Sassolas; J A Chayvialle; C Partensky; G Berger; J Trouillas; F Berger; B Claustrat; R Cohen; C Girod; R Guillemin
Journal:  Ann Endocrinol (Paris)       Date:  1983       Impact factor: 2.478

9.  Plasma growth hormone response to growth hormone-releasing factor in acromegalic patients.

Authors:  T Shibasaki; K Shizume; A Masuda; M Nakahara; N Hizuka; M Miyakawa; K Takano; H Demura; I Wakabayashi; N Ling
Journal:  J Clin Endocrinol Metab       Date:  1984-01       Impact factor: 5.958

10.  Growth hormone responsiveness to human pancreatic growth hormone releasing factor in acromegaly: modulatory effects of basal hormone levels and of concomitant somatostatin administration.

Authors:  G F Pieters; A E Smals; A R Hermus; A G Smals; T J Benraad; P W Kloppenborg
Journal:  Clin Endocrinol (Oxf)       Date:  1984-12       Impact factor: 3.478
View more
  1 in total

Review 1.  Neuroendocrine regulation of human growth hormone secretion. Diagnostic and clinical applications.

Authors:  G Delitala; P Tomasi; R Virdis
Journal:  J Endocrinol Invest       Date:  1988-06       Impact factor: 4.256
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.